A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

NCT02924688 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2436

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: FF/UMEC/VI (100/31.25/25) mcg
DRUG: FF/UMEC/VI (100/62.5/25) mcg
DRUG: FF/UMEC/VI (200/31.25/25) mcg
DRUG: FF/UMEC/VI (200/62.5/25) mcg
DRUG: FF/VI (100/25) mcg
DRUG: FF/VI (200/25) mcg
DRUG: Fluticasone/salmeterol (FSC)
DRUG: Albuterol/salbutamol
DEVICE: ELLIPTA DPI
DEVICE: DISKUS DPI
DEVICE: METERED-DOSE INHALER (MDI)

Sponsor

GlaxoSmithKline